跳至主要内容
临床试验/NCT00951418
NCT00951418已完成不适用

Serum Clozapine and Cognition

University of Aarhus1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2009年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
Cognitive function measured by CANTAB

研究概览

简要总结

This study aim to investigate the relationship between serum levels of clozapine and cognitive performance in patients with ICD-10 Schizophrenia and treated with clozapine monotherapy. The hypothesis is that higher serum levels of clozapine are associated with cognitive dysfunctions. Furthermore, ECG changes and the relation to serum level of clozapine are studied. The design is cross-sectional.

研究设计

研究类型
Observational
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Treated with clozapine for minimum 6 months.
  • Fixed dosage of clozapine last month before inclusion.

排除标准

  • Substance misuse.
  • Depression (Calgary Depression score ≥7).
  • Somatic disease that interfere with cognitive performance.
  • Treatment with benzodiazepines (half-lives >15 hours not allowed up 14 days prior inclusion and during study. Half-lives < 15 hours not allowed 3 days prior cognitive testing).
  • Electroconvulsive therapy.
  • Treatment with other antipsychotics.
  • Withdrawal of informed consent.
  • Compulsory measures.
  • Treatment with anticholinergics except for atropine drops administered sublingually.
  • Changes in use of tobacco last month before inclusion.

结局指标

主要结局

Cognitive function measured by CANTAB

时间窗: once

次要结局

  • T-wave morphology(Once)
  • Sedation VAS,ACES and SWAI scale(once)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验